ã¤ã®ãªã¹ã§ãåºç¤ç¾æ£ã®ãªã21æ³ã®å¥³æ§ãæ°åã³ããã¦ã¤ã«ã¹ã«ããææçï¼COVID-19ï¼ã§æ»äº¡ãã¦ãããã¨ãæããã«ãªã£ãã

ã¤ã®ãªã¹ã§ãåºç¤ç¾æ£ã®ãªã21æ³ã®å¥³æ§ãæ°åã³ããã¦ã¤ã«ã¹ã«ããææçï¼COVID-19ï¼ã§æ»äº¡ãã¦ãããã¨ãæããã«ãªã£ãã
æ±äº¬é½ã¯ãï¼æ¥ã«çºè¡¨ããææè ã®æ°ã¨ãã¦ã¯ããã¾ã§ã§æãå¤ãããããã¦41人ããæ°ãã«æ°åã³ããã¦ã¤ã«ã¹ã«ææãã¦ãããã¨ã確èªããã¨çºè¡¨ãã¾ãããå°æ± ç¥äºã¯25æ¥å¤ãç·æ¥ã®è¨è ä¼è¦ãéãããä»ã®ç¶æ³ãææççºã®é大å±é¢ã¨ã¨ãããã®èªèãå ±æããããã¨è¿°ã¹ã¦å¼·ã屿©æã示ããããã§ãå¹³æ¥ã¯ã§ããã ãèªå® ã§ä»äºãè¡ã£ã¦å¤éã®å¤åºãæ§ããç¹ã«ä»é±æ«ã¯ä¸è¦ä¸æ¥ã®å¤åºãæ§ããããå¼ã³ããã¾ããã æ±äº¬é½ã¯ã25æ¥å¤ãå°æ± ç¥äºãç·æ¥ã®è¨è ä¼è¦ãéããç·å¥³åããã¦41äººãæ°ãã«æ°åã³ããã¦ã¤ã«ã¹ã«ææãã¦ãããã¨ã確èªããã¨çºè¡¨ãã¾ããã ï¼æ¥ã«çºè¡¨ããææè æ°ã¨ãã¦ã¯ããã¾ã§ã§æãå¤ãã£ã24æ¥ã®17人ã®ï¼å以ä¸ã¨ãªãã¾ããã çºè¡¨ã«ããã¾ãã¨ã41人ã®ãã¡11人ãã24æ¥ã¾ã§ã«çè·å¸«ã¨æ£è åããã¦ï¼äººã®ææã確èªããã¦ããå°æ±åºã«ããæ°¸å¯¿ç·åç é¢ã®æ£è ãå»çå¾äºè ã ã¨ãããã¨ã§ãã ã¾ããï¼äººã¯ã
çéä¿æ¨¹ [ä¸å¤®å¤§å¦å¤§å¦é¢æ¦ç¥çµå¶ç ç©¶ç§ææã夿©å¤§å¦å¤§å¦é¢ç¹ä»»ææãåå¤å±å¤§å¦æªæ¥ç¤¾ä¼åµé æ©æ§å®¢å¡ææãå»å¸«] 1987å¹´åå¤å±å¤§å¦å»å¦é¨åæ¥ãå»å¸«ãå»å¦å士ãçµæ¸å¦å士ãç·åå ç§å°éå»ãæ¥æ¬å»å¸«ä¼èªå®ç£æ¥å»ãMBAããè¨åºå»ã製è¬ä¼æ¥ã®ããã¸ã¡ã³ããçµã¦ãç¾å¨ãä¸å¤®å¤§å¦å¤§å¦é¢æ¦ç¥çµå¶ç ç©¶ç§ææã夿©å¤§å¦å¤§å¦é¢ç¹ä»»ææãåºçã»è¬æ¼ãå¤ããå»çã»ä»è·æ¥çã«ããã¸ã¡ã³ããã¤ããã¼ã·ã§ã³ã®è¦ç¹ã§æ¹é©ãèãã¦ããã DOLç¹å¥ã¬ãã¼ã å å¤ã®æ¿æ²»ãçµæ¸ãç£æ¥ã社ä¼åé¡ã«åã¶å¹ åºããã¼ããæ¬æ°ãªè¦ç¹ã§åæãããåæã¬ãã¼ãããã³èè ã»å°éå®¶ã«ããç¹å¥å¯ç¨¿ã ããã¯ãã³ãã¼ä¸è¦§ æ¬§ç±³ã§æ°åã³ããã¦ã¤ã«ã¹ã®æææ¡å¤§ãç¶ãã¦ãããç¹ã«ã¤ã¿ãªã¢ã§ã®æ»äº¡è ã¯çºçæºã®ä¸å½ãä¸åãã»ã©ã®ã²ã©ãç¶æ³ã¨ãªã£ã¦ããããªããã¤ã¿ãªã¢ã§ã¯ããã»ã©æ»äº¡è ãå¢ãã¦ãã¾ã£ãã®ããå°æ¥çã«æ¥æ¬ã¯ã¤ã¿ãªã¢ã®ãããªç¶æ ã«ãªãããã®ã
æ°åã³ããã¦ã¤ã«ã¹ã§æ»äº¡ãã人ãä¸çã§æãå¤ãã¤ã¿ãªã¢ã§ã¯21æ¥ãæ°ãã«800人è¿ãã亡ããªããæ»äº¡è ã®æ°ã¯4825人ã¨ãªãã¾ãããææè ãï¼ä¸3578人ã«ä¸ã£ã¦ãã¾ãã ãã®ãããä¸å¿é½å¸ãã©ãããããã80ããé¢ããã¯ã¬ã¢ãã®ç é¢ã§ã¯ãã¢ã¡ãªã«ã®ï¼®ï¼§ï¼¯ã®æ¯æ´ã§é䏿²»ç室ãåããéå¤ç é¢ãè¨ç½®ããããªã©æ å¢ãå¼·åããã¾ããã 䏿¹ãã¤ã¿ãªã¢æ¿åºã¯ææã®æ¡å¤§ãæããããã¨ãã¦å¤åºã®è¦å¶ã䏿®µã¨å³ãããã21æ¥ããã¯å ¨åã§ãã¹ã¦ã®å ¬åãééããã»ããèªå® å¨è¾ºã§ãªããã°ã¸ã§ã®ã³ã°ãªã©ã®éåãèªããªãã¨ãã¦ãã¾ãã 対çãå¾¹åºãããããè¦å¯å®ã«ããç£è¦ãå¼·ã¾ã£ã¦ãã¦ãé¦é½ãã¼ãã®ä¸å¿é¨ã§ã¯ããµã ãã¯è¦³å 客ã§ã«ãããã¹ãã¤ã³åºå ´ãã»ã¨ãã©äººã®å§¿ããªãè¡ãä¸å¤ãã¦ãã¾ããåºå ´è¿ãã§ã¸ã§ã®ã³ã°ããã¦ããç·æ§ãè¦å¯å®ã«å¼ã³æ¢ããããæ³¨æãåããå ´é¢ãã¿ããã¾ããã 主è¦ãªéè·¯ã§ã¯æ¤åãè¡ãããè¦å¯å®ãé
ã¤ã¿ãªã¢å½å±ã¯ï¼ï¼æ¥ãæ°åã³ããã¦ã¤ã«ã¹ææã«ããæ»è ã忥ããï¼ï¼ï¼äººï¼ï¼ï¼ï¼ï¼ï¼ ï¼å¢å ããï¼ï¼ï¼ï¼äººã«ãªã£ãã¨çºè¡¨ãããåçã¯ãã¼ãã§ï¼æï¼ï¼æ¥æ®å½±ï¼ï¼ï¼ï¼ï¼å¹´ããã¤ã¿ã¼/Alberto Lingriaï¼ ï¼»ãã¼ããï¼ï¼æ¥ããã¤ã¿ã¼ï¼½ - ã¤ã¿ãªã¢å½å±ã¯ï¼ï¼æ¥ãæ°åã³ããã¦ã¤ã«ã¹ææã«ããæ»è ã忥ããï¼ï¼ï¼äººï¼ï¼ï¼ï¼ï¼ï¼ ï¼å¢å ããï¼ï¼ï¼ï¼äººã«ãªã£ãã¨çºè¡¨ãããï¼æ¥ã®å¢å ã¨ãã¦ã¯åã®ææã確èªããã¦ããæå¤§ã
大éªã»å µåº«ãæ£è ï¼ï¼ï¼ï¼äººã«ããåå´ç試ç®ãåºãå ¬éâæ°åã³ãã 2020å¹´03æ20æ¥18æ44å åæã«å¿ãã大éªåºã®åææ´æç¥äºï¼ï¼ï¼æ¥åå¾ãååºåº 大éªåºã¯ï¼ï¼æ¥ãæ°åã³ããã¦ã¤ã«ã¹å¯¾çæ¬é¨ä¼è°ãéããåçå´åçãåºã¨å µåº«çã«ææ¡ããç·æ¥å¯¾çæ¡ã®ææ¸ãå ¬éãããææ¸ã§åçã¯ãï¼ä¸¡åºçã®ï¼å ¨åã§è¦ããªãã¯ã©ã¹ã¿ã¼é£éãå¢å ãã¤ã¤ãããææã®æ¥æ¿ãªå¢å ãå§ã¾ã£ã¦ããã¨èãããããã¨ç¾ç¶åæããï¼ï¼æ¥ããï¼æï¼æ¥ã¾ã§ã®éã«ã両åºçã®æ£è æ°ãï¼ï¼ï¼ï¼äººããã¡é篤è ã¯ï¼ï¼ï¼äººã«éããã¨ã®è©¦ç®ã示ããã ãææ°æ å ±ãæ°åã³ããã¦ã¤ã«ã¹ åå´çã¯ã両åºçã§æææºã®ä¸æãªçä¾ãå¢å ãã¦ãããå µåº«çã§ã¯ï¼äººã®ææè ãå¹³åãã¦ãã¤ã人æ°ãï¼ãè¶ ããã¨ææãä»å¾ãææè ãæ¥éã«å¢å ããæ¥é±ã«ã¯éçè ã¸ã®å»çæä¾ãé£ãããªãå¯è½æ§ãããã¨ããã ãã®ä¸ã§å¯¾çã¨ãã¦ã両åºçã§ã®ä¸è¦ä¸æ¥ã®è¡ãæ¥ã®èªç²ã«å ãã
ã¢ããªã«è«¸å½ã§æ°åã³ããã¦ã¤ã«ã¹ã®ææãæ¥æ¡å¤§ããå ¥å½ç¦æ¢ãéå¸¸äºæ 宣è¨ã«è¸ã¿åãå½ãç¸æ¬¡ãã§ãããä¸å½ãæ¬§ç±³ã«æ¯ã¹ãã¨ææè æ°ã¯å°ãªããã®ã®ãå»çä½å¶ãèå¼±ï¼ãããããï¼ãªå½ãå°åãå¤ããã¨ãããâ¦
ãã¯ã·ã³ãã³=鳳山太æãç±³å½åçã¯19æ¥ãæ°åã³ããã¦ã¤ã«ã¹ã®æææ¡å¤§ãè¸ã¾ãããã¹ã¦ã®å¤å½ã¸ã®æ¸¡èªã䏿¢ããããç±³å½äººã«å§åãããããã¾ã§ã¯ä¸å½ãªã©ææè ãå¤ãå½ã»å°åã対象ã«ãã¦ããããå ¨ä¸çã«åºãããä¸çåå½ãåºå ¥å½å¶éã宿½ãã¦ããã»ããèªç©ºä¾¿ãæ¸ã£ã¦ããã帰å½ã§ããªãæããããã¨è¦åããã人ã®å¾æ¥ãæ»ããçµæ¸ã¸ã®å½±é¿ã¯ä¸æ®µã¨åºããããã ãå ¨ä¸çã«å¯¾ããæ¸¡èªè¦æã¬ãã«ãæé«ã®ãã¬ãã«4
é½å ã®ç é¢ã«å¤åãã¦ããç¥äººããè¡æçãªè©±ãèããã ãPCRæ¤æ»ããæ¤ä½ã¯å ¨ã¦ç ´æ£ãã¦ãæ£è ã«ã¯é°æ§ã¨ä¼ãã¦ãããããã ã ä¸ããæ¯æããã¦æ¯æ¥æ¯æ¥æ¤ä½ãæ¨ã¦ã¦ã¯åãã¤ãã®ããã©ã¤ã¨åãã¦ããã ãªãã ããâ¦
大éªåºã®åæç¥äºã¯19æ¥å¤ãç·æ¥ã®è¨è ä¼è¦ãéãã20æ¥ããã®ï¼é£ä¼ãæ°åã³ããã¦ã¤ã«ã¹ã®æææ¡å¤§ãé²ãããã大éªåºã¨å µåº«çã®éã®ä¸è¦ä¸æ¥ã®å¾æ¥ãæ§ããããæ±ãã¾ããã åæç¥äºã¯ãã®çç±ã«ã¤ãã¦ãå½ã®å°éå®¶ãã大éªåºã»å µåº«çã«ãããç·æ¥å¯¾çã®ææ¡ãããã ãããå ¨å½çã«ãææè ãå¢ãã¦ããä¸ã§ãç¹ã«å µåº«çã¯ï¼äººã®ææè ãï¼æ¬¡ææè ãçã¿åºãå¹³åå¤ãï¼ãè¶ ãã¦ãããççºçãªææããã¤èµ·ãã¦ããããããªã大éªã¯ï¼ãè¶ ãã¦ããªãããææè ãå¢ãã¦ãã¦è¦æããªãã¨ãããªãç¶æ³ã ãå½ã®è©¦ç®ã§ã¯å¤§éªã¨å µåº«ã§æ¬¡ã®ï¼æ¥éã§ææè ã586人ã¨ãªããããã«æ¬¡ã®ï¼æ¥éã§3374人ã¨ãªãéçè ã¯227人ã¨ãªã£ã¦ãããããã¯ææªãæ¥éã«ææãæ¡å¤§ããã°ãããªãã¨ãã試ç®çµæã ããã®äºæ ãéãåãæ¢ãã20æ¥ããã®ï¼é£ä¼ã徿¥ãæ§ãã¦ããã ããããã¨èª¬æãã¾ããã ãã®ããã§ãä¸è¦ä¸æ¥ãã©ããã¯åå¥ã§å¤æãããããªã
ã¤ã¹ã©ã¨ã«ã»ã¢ã·ã¥ãããã®ç é¢ã§ãæ°åã³ããã¦ã¤ã«ã¹æ£è ã®æ²»çæ å¢ãè¨è ãã«å ¬éããè·å¡ï¼2020å¹´3æ16æ¥æ®å½±ï¼ã(c)JACK GUEZ / AFP ã3æ17æ¥ AFPãä¸çä¿å¥æ©é¢ï¼WHOï¼ã¯16æ¥ãæ°åã³ããã¦ã¤ã«ã¹ææçï¼COVID-19ï¼ã®çãã®ããæ£è å ¨å¡ãæ¤æ»ããããåå½ã«å¼ã³æãããWHOã¯ã¾ããä¸å½ãé¤ãä¸çã®ææè æ°ã¨æ»è æ°ã¯ä¸å½ãä¸åã£ãã¨æããã«ããã ãå³è§£ãæ°åã³ããã¦ã¤ã«ã¹ï¼ææãããã©ããªãï¼ WHOã®ãããã¹ã»ã¢ããã ã»ã²ãã¬ã¤ã§ã¹ã¹ï¼Tedros Adhanom Ghebreyesusï¼äºåå±é·ã¯ãã¹ã¤ã¹ã»ã¸ã¥ãã¼ãã§ã®è¨è ä¼è¦ã§ããç®é ããããã¾ã¾çã¨éããã¨ã¯ã§ããªããã¨è¨æãWHOã¯åå½ã«å¯¾ãããæ¤æ»ãæ¤æ»ãæ¤æ»ãçãã®ããæ£è å ¨å¡ãæ¤æ»ãããããå§åãã¦ããã¨è¿°ã¹ãã ãããã¹æ°ã¯ããã«ãããã®1é±éã§COVID-19æ£è ã¯æ¥å¢ãããã¨ææ
ãªãªã¼ã¹ãé害æ å ±ãªã©ã®ãµã¼ãã¹ã®ãç¥ãã
ææ°ã®äººæ°ã¨ã³ããªã¼ã®é ä¿¡
å¦çãå®è¡ä¸ã§ã
j次ã®ããã¯ãã¼ã¯
kåã®ããã¯ãã¼ã¯
lãã¨ã§èªã
eã³ã¡ã³ãä¸è¦§ãéã
oãã¼ã¸ãéã
{{#tags}}- {{label}}
{{/tags}}